Researchers have long wondered why some older people remain cognitively normal despite having abnormal levels of beta-amyloid in their brains, a hallmark of Alzheimer’s disease. While research has shown that older adults with Mild Cognitive Impairment (MCI), which often leads to Alzheimer’s, frequently have increased activity in the hippocampus compared to their cognitively healthy peers, scientists questioned what the hyperactivity represented. Was it helping to compensate for declining brain function or signaling onset of the disease?
A randomized clinical trial of estrogen therapy in younger postmenopausal women, aged 50–55, has found no long-term risk or benefit to cognitive function. The National Institutes of Health-supported study, reported in JAMA Internal Medicine on June 24, 2013, looked at women taking conjugated equine estrogens, the most common type of postmenopausal hormone therapy in the United States.
The earlier Women’s Health Initiative Memory Study (WHIMS) linked the same type of hormone therapy to cognitive decline and dementia in older postmenopausal women.
What’s the difference between mild forgetfulness and more serious memory problems? Find out about memory problems, including Alzheimer's disease and dementia, and how to get help for serious memory loss.
An updated service from the Alzheimer’s Disease Education and Referral (ADEAR) is making it easier than ever for people to find clinical research studies that are testing new ways to detect, treat, delay and prevent Alzheimer’s disease, mild cognitive impairment and other dementias.
The neuropathology guidelines used since 1997 to diagnose Alzheimer’s disease at autopsy have been updated to reflect a deeper understanding of Alzheimer’s and other dementias. This will help pathologists characterize Alzheimer’s-related brain changes at death in people diagnosed with dementia and those who have not yet shown clinical symptoms.
A nicotine skin patch may improve cognition in older people with mild cognitive impairment (MCI), a condition marked by memory loss that often leads to Alzheimer’s dementia, according to findings from a small pilot clinical trial reported in the Jan. 10, 2012 print issue of Neurology. Nearly 70 volunteers, all non-smokers, wore either a nicotine patch or a placebo patch during the six month trial supported by the NIH. Researchers measured the volunteers’ cognitive performance at the start, at three months and at the end of the trial.
Results of a pilot clinical trial show a nasal-spray form of insulin delayed memory loss and preserved cognition in people with cognitive deficits that range from mild cognitive impairment (MCI) to moderate Alzheimer’s disease. Researchers at the Veterans Affairs Puget Sound Health Care System in Seattle led the trial, which was supported in large part by the NIA.